PB 9 of 2015
National Health (Weighted average disclosed price –April 2015 reduction day) Amendment Determination 2015 (No.1)
National Health Act 1953
I, FELICITY MCNEILL, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this determination under subsection 99ADB(4) of the National Health Act 1953.
Dated: 25 February 2015
 
 
 
 
 
 
 
 
 
FELICITY MCNEILL
 
First Assistant Secretary
Pharmaceutical Benefits Division
Department of Health
 
1              Name of Determination
       (1)     This Determination is the National Health (Weighted average disclosed price – April 2015 reduction day) Amendment Determination 2015 (No.1).
       (2)     This Determination may also be cited as PB 9 of 2015.
2              Commencement
                This Determination commences on the day after it is registered.
 
3                   Amendments to PB 97 of 2014
Schedule 1 amends the National Health (Weighted average disclosed price – April 2015 reduction day) Determination 2014 (PB 97 of 2014).
Schedule 1       Amendments
 
[1]     Schedule 1
omit:
152
Aspirin
Tablet 100 mg
Oral
Astrix
0.96

153
Aspirin
Tablet 100 mg
Oral
Mayne Pharma Aspirin
0.96

154
Aspirin
Tablet 100 mg
Oral
Spren 100
0.96

155
Aspirin
Tablet, dispersible, 300 mg
Oral
Solprin
1.23

 
[2]     Schedule 1
omit:
582
Exemestane
Tablet 25 mg
Oral
APO-Exemestane
71.33

583
Exemestane
Tablet 25 mg
Oral
Aromasin
71.33

584
Exemestane
Tablet 25 mg
Oral
Exaccord
71.33

585
Exemestane
Tablet 25 mg
Oral
Exemestane AN
71.33

586
Exemestane
Tablet 25 mg
Oral
Exemestane GH
71.33

587
Exemestane
Tablet 25 mg
Oral
Exemestane Pfizer
71.33

588
Exemestane
Tablet 25 mg
Oral
Exemestane Sandoz
71.33

589
Exemestane
Tablet 25 mg
Oral
Exemestane-GA
71.33

substitute:
582
Exemestane
Tablet 25 mg
Oral
APO-Exemestane
84.64

583
Exemestane
Tablet 25 mg
Oral
Aromasin
84.64

584
Exemestane
Tablet 25 mg
Oral
Exaccord
84.64

585
Exemestane
Tablet 25 mg
Oral
Exemestane AN
84.64

586
Exemestane
Tablet 25 mg
Oral
Exemestane GH
84.64

587
Exemestane
Tablet 25 mg
Oral
Exemestane Pfizer
84.64

588
Exemestane
Tablet 25 mg
Oral
Exemestane Sandoz
84.64

589
Exemestane
Tablet 25 mg
Oral
Exemestane-GA
84.64

 
[3]     Schedule 1
omit:
1080
Macrogol 3350
Oral liquid 13.125 g with electrolytes, 500 mL
Oral
Movicol Liquid
6.37
substitute:
1080
Macrogol 3350
Oral liquid 13.125 g in 25 mL with electrolytes, 500 mL
Oral
Movicol Liquid
6.37
 
[4]     Schedule 1
omit:
1259
Nevirapine
Tablet 200 mg
Oral
Nevipin
166.60

1260
Nevirapine
Tablet 200 mg
Oral
Nevirapine Alphapharm
166.60

1261
Nevirapine
Tablet 200 mg
Oral
Nevirapine RBX
166.60

1262
Nevirapine
Tablet 200 mg
Oral
Viramune
166.60

1263
Nevirapine
Tablet 400 mg (extended release)
Oral
Viramune XR
166.60

substitute:
1259
Nevirapine
Tablet 200 mg
Oral
Nevipin
198.09

1260
Nevirapine
Tablet 200 mg
Oral
Nevirapine Alphapharm
198.09

1261
Nevirapine
Tablet 200 mg
Oral
Nevirapine RBX
198.09

1262
Nevirapine
Tablet 200 mg
Oral
Viramune
198.09

1263
Nevirapine
Tablet 400 mg (extended release)
Oral
Viramune XR
198.09

 
[5]     Schedule 1
after:
2075
Tramadol
Tablet (sustained release) containing tramadol hydrochloride 200 mg
Oral
Zydol SR 200
4.14
 omit:
2076
Tramadol
Tablet (sustained release) containing tramadol hydrochloride 50 mg
Oral
Tramal SR 50
1.76
 
[6]     Schedule 2
after:
99
Ampicillin
Powder for injection 500 mg (as sodium)
Injection
Ibimicyn
3.09
insert:
99A
Aspirin
Tablet 100 mg
Oral
Astrix
1.07

99B
Aspirin
Tablet 100 mg
Oral
Mayne Pharma Aspirin
1.07

99C
Aspirin
Tablet 100 mg
Oral
Spren 100
1.07

99D
Aspirin
Tablet, dispersible, 300 mg
Oral
Solprin
1.37

 
[7]     Schedule 2
omit:
1416
Sodium chloride
I.V. infusion 154 mmol per L. 1 L
Injection
Baxter Healthcare Pty Ltd
1.27
substitute:
1416
Sodium chloride
I.V. infusion 154 mmol per L, 1 L
Injection
Baxter Healthcare Pty Ltd
1.27